Poteligeo Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing incidence of rare t-cell lymphomas, regulatory approvals for targeted biologics, growing oncology drug research investments, expansion of specialty cancer treatment centers, improved diagnostic capabilities for ctcl and atll.

The growth in the forecast period can be attributed to rising demand for precision oncology drugs, increasing adoption of biologics in hematologic cancers, expansion of personalized medicine approaches, growing investments in advanced biologic manufacturing, increasing focus on rare cancer treatment pipelines. Major trends in the forecast period include increasing adoption of targeted immunotherapy treatments, rising focus on ccr4-targeted oncology therapies, expansion of monoclonal antibody manufacturing capabilities, growing emphasis on personalized cancer treatment protocols, enhanced clinical monitoring of rare t-cell malignancies.

The increasing prevalence of lymphoma is expected to drive the growth of the poteligeo market moving forward. Lymphoma is a type of cancer that originates in the lymphatic system, which is part of the immune system, affecting the lymph nodes, spleen, and bone marrow. The rising incidence of lymphoma is linked to factors such as an aging population, greater exposure to environmental risk factors, and advancements in diagnostic technologies. Poteligeo (mogamulizumab) aids in the treatment of lymphoma by targeting and inhibiting the CCR4 receptor on cancerous T-cells, thus reducing tumor growth and enhancing the immune system's response against cancer cells. For example, in 2023, the American Cancer Society, a US-based non-profit organization, reported that the estimated number of new lymphoma cases increased from 89,010 in 2022 to 89,380 in 2023. As a result, the growing prevalence of lymphoma is driving the expansion of the poteligeo market.

Leading companies in the poteligeo market are focusing on technological advancements such as CCR4-targeted monoclonal antibody therapies, which offer more precise treatment for cutaneous T-cell lymphoma. These therapies improve efficacy and minimize off-target effects when compared to traditional chemotherapy. A CCR4-targeted monoclonal antibody binds to the CC chemokine receptor 4 on malignant T-cells, triggering antibody-dependent cellular cytotoxicity (ADCC), which selectively destroys cancer cells while sparing healthy tissue. For instance, in September 2023, Kyowa Kirin International, a Japan-based specialty pharmaceutical company, presented real-world evidence for Poteligeo (mogamulizumab) at the EORTC CLTG meeting. The evidence, gathered from multiple international registries, demonstrated consistent safety and effectiveness in routine clinical practice, beyond controlled trials, which supports broader adoption and clinical confidence in the treatment of CCR4-positive cutaneous T-cell lymphoma.

In January 2025, Kyowa Kirin, in partnership with Swixx BioPharma, a Switzerland-based provider of pharmaceutical distribution and commercialization services, aimed to expand access to Poteligeo (mogamulizumab) for adults with mycosis fungoides or Sézary syndrome in Central and Eastern Europe, including countries like Croatia and Bulgaria. This collaboration seeks to improve patient access, facilitate reimbursement, and enhance local commercial support for Poteligeo. This partnership underscores the poteligeo market’s growing emphasis on regional expansion and improving the availability of CCR4-targeting therapies.

Major companies operating in the poteligeo market are Kyowa Kirin Co. Ltd.

North America was the largest region in the poteligeo market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the poteligeo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the poteligeo market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the poteligeo market by increasing costs of imported biologic raw materials, specialized reagents, manufacturing equipment, and cold-chain logistics used in monoclonal antibody production. North America and Europe are most affected due to reliance on globally sourced biologics inputs, while Asia-Pacific faces higher costs in contract manufacturing and export-oriented production. These tariffs are raising production expenses and influencing drug pricing strategies for oncology therapies. However, they are also encouraging localized biologics manufacturing, regional supply chain diversification, and long-term investments in domestic biopharmaceutical production infrastructure.

The poteligeo market research report is one of a series of new reports that provides poteligeo market statistics, including poteligeo industry global market size, regional shares, competitors with a poteligeo market share, detailed poteligeo market segments, market trends and opportunities, and any further data you may need to thrive in the poteligeo industry. This poteligeo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Poteligeo is a monoclonal antibody used to treat specific cancers, including cutaneous T-cell lymphoma (CTCL) and adult T-cell leukemia/lymphoma (ATLL). It works by targeting and inhibiting the CCR4 receptor on the surface of cancerous T-cells in these cancers. By binding to CCR4, it helps reduce the proliferation of these malignant cells and may lead to their destruction.

The primary indications for poteligeo include mycosis fungoides, sezary syndrome, and peripheral T-cell lymphoma (PTCL). Mycosis fungoides is a rare form of cutaneous T-cell lymphoma marked by abnormal T-cell growth in the skin, resulting in lesions. Poteligeo is distributed through various channels such as direct sales by pharmaceutical companies, wholesale distributors, and retail pharmacies, and is used by a range of end users, including hospitals, oncology clinics, and home healthcare providers.

The poteligeo market consists of sales of mogamulizumab injection. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.